Stroke

A First in Class Product that can act as a “Platform” Applicable to Multiple Diseases

Commercialization: STROKE

IND # 27375
32 patient clinical trial, 3 doses, one placebo, 8 patients per group
Purpose is determining safety and efficacy of intravenously administered ImmCelz® cells in patients with acute stroke
7-30 days after onset
Modified Rankin Scale (mRS) for disability, NIHSS for determining neurological impairment, and Barthel Index (BI) for activities of daily living
Toxicity of treatment was evaluated for the duration of the study and will be graded according to the criteria of the World Health Organization